{"cdcTestId":"2018-0005","testcaseName":"Zoster: Dose #2 (Shingrix) administered at 4 weeks - 1 days after dose #1","vaccineGroup":"ZOSTER","evaluationTestType":"Interval: At Absolute Minimum ","forecastTestType":"Not recommended: series complete","assessmentDate":"2022-10-19T00:00:00","patient":{"dob":"1972-09-21T00:00:00","gender":"M"},"evaluation":{"seriesStatus":"Complete","administeredDoses":[{"dateAdministered":"2022-09-21T00:00:00","vaccineName":"zoster recombinant","cvx":"187","mvx":"","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2022-10-18T00:00:00","vaccineName":"zoster recombinant","cvx":"187","mvx":"","evaluationStatus":"Valid","evaluationReason":null}]},"forecast":{"forecastNum":"","earliestDate":"0001-01-01T00:00:00","recommendedDate":"0001-01-01T00:00:00","pastDueDate":"0001-01-01T00:00:00"},"doses":[{"dateAdministered":"2022-09-21T00:00:00","vaccineName":"zoster recombinant","cvx":"187","mvx":"","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2022-10-18T00:00:00","vaccineName":"zoster recombinant","cvx":"187","mvx":"","evaluationStatus":"Valid","evaluationReason":null}],"dateAdded":"2018-03-27T20:00:00","dateUpdated":"2020-05-29T08:33:46.927","generalDescription":"This test case describes when an adult patient is administered the second dose of Shingrix vaccine at 4 weeks - 1 day, that the dose is considered to be valid.","changedInVersion":"4.0","reasonForChange":"V4.0 Per SME Guidance, the four day grace period can be used. Second dose has been changed to \u0022valid\u0022.\nV3.5: Previous version was calculating the forecast from the first dose. This has been corrected to be from the previous dose (invalid dose #2)."}